Tuberculosis (TB), although preventable and curable, remains a global health threat. An estimated 10.6 million people fell ill with TB in 2022, resulting in an estimated 1.3 million deaths worldwide, far from the 2025 milestone of the End TB Strategy by the WHO. Moreover, anti-TB drug resistance,particularly MDR-TB (resistant to RIF & INH), is increasingly challenging the global TB treatment and prevention.
Efficient and accurate TB and anti-TB drug resistance diagnosis is the KEY to the success of TB treatment and prevention.